MX2018007295A - Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos. - Google Patents

Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos.

Info

Publication number
MX2018007295A
MX2018007295A MX2018007295A MX2018007295A MX2018007295A MX 2018007295 A MX2018007295 A MX 2018007295A MX 2018007295 A MX2018007295 A MX 2018007295A MX 2018007295 A MX2018007295 A MX 2018007295A MX 2018007295 A MX2018007295 A MX 2018007295A
Authority
MX
Mexico
Prior art keywords
specific
disease
antigen
lymphocytes
cells
Prior art date
Application number
MX2018007295A
Other languages
English (en)
Spanish (es)
Inventor
Mccauley Scott
Brian MUMM John
Ho CHAN Ivan
Oft Martin
Ogg Scott
Original Assignee
Armo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Armo Biosciences Inc filed Critical Armo Biosciences Inc
Publication of MX2018007295A publication Critical patent/MX2018007295A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2018007295A 2016-01-11 2017-01-10 Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos. MX2018007295A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662277442P 2016-01-11 2016-01-11
PCT/US2017/012882 WO2017123557A1 (en) 2016-01-11 2017-01-10 Interleukin-10 in production of antigen-specific cd8+ t cells and methods of use of same

Publications (1)

Publication Number Publication Date
MX2018007295A true MX2018007295A (es) 2019-03-28

Family

ID=59311424

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007295A MX2018007295A (es) 2016-01-11 2017-01-10 Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos.

Country Status (9)

Country Link
US (1) US11814679B2 (cg-RX-API-DMAC7.html)
EP (1) EP3402512A4 (cg-RX-API-DMAC7.html)
JP (1) JP7082051B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180101417A (cg-RX-API-DMAC7.html)
CN (1) CN108697776A (cg-RX-API-DMAC7.html)
AU (1) AU2017207282A1 (cg-RX-API-DMAC7.html)
CA (1) CA3008287A1 (cg-RX-API-DMAC7.html)
MX (1) MX2018007295A (cg-RX-API-DMAC7.html)
WO (1) WO2017123557A1 (cg-RX-API-DMAC7.html)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201400513PA (en) 2011-09-08 2014-06-27 Yeda Res & Dev Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
AU2016291825B2 (en) 2015-07-16 2022-08-11 Yeda Research And Development Co. Ltd. Genetically modified anti-third party central memory T cells and use of same in immunotherapy
KR102634093B1 (ko) 2016-10-28 2024-02-07 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법
CN110072890B (zh) 2016-11-03 2022-11-29 百时美施贵宝公司 可活化的抗ctla-4抗体及其用途
ES3064681T3 (en) 2017-01-18 2026-04-28 Yeda Res & Dev Genetically modified veto cells and use of same in immunotherapy
EP3601355A1 (en) 2017-03-31 2020-02-05 Bristol-Myers Squibb Company Methods of treating tumor
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
WO2018222718A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
JP7301002B2 (ja) 2017-05-30 2023-06-30 ブリストル-マイヤーズ スクイブ カンパニー 抗lag-3抗体または抗lag-3抗体および抗pd-1もしくは抗pd-l1抗体を含む組成物
JP2020522495A (ja) 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 抗lag−3抗体、pd−1経路阻害剤および免疫療法剤の組み合わせを含む組成物
EP3630840A1 (en) 2017-06-01 2020-04-08 Bristol-Myers Squibb Company Methods of treating a tumor using an anti-pd-1 antibody
US11351163B2 (en) 2017-09-29 2022-06-07 Bristol-Myers Squibb Company Compositions and methods of treating cancer
EP3694884A1 (en) 2017-10-15 2020-08-19 Bristol-Myers Squibb Company Methods of treating tumor
KR20200084880A (ko) 2017-11-06 2020-07-13 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
KR20200109339A (ko) 2018-01-16 2020-09-22 브리스톨-마이어스 스큅 컴퍼니 Tim3에 대한 항체를 사용하여 암을 치료하는 방법
AU2019210332A1 (en) 2018-01-22 2020-09-10 Pascal Biosciences Inc. Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
SG11202006823XA (en) 2018-01-22 2020-08-28 Bristol Myers Squibb Co Compositions and methods of treating cancer
AU2019240370B2 (en) * 2018-03-23 2024-03-07 Gavish-Galilee Bio Applications Ltd. Genetically reprogrammed Tregs expressing membrane-bound IL-10
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル-マイヤーズ スクイブ カンパニー Micaおよび/またはmicbに対する抗体ならびにそれらの使用
EP3774911A1 (en) 2018-03-30 2021-02-17 Bristol-Myers Squibb Company Methods of treating tumor
EP3774903A1 (en) 2018-04-04 2021-02-17 Bristol-Myers Squibb Company Anti-cd27 antibodies and uses thereof
JP7097465B2 (ja) * 2018-06-19 2022-07-07 アルモ・バイオサイエンシーズ・インコーポレイテッド キメラ抗原受容体細胞療法と併用するil-10剤の組成およびその使用方法
AU2019309849A1 (en) 2018-07-26 2021-03-18 Bristol-Myers Squibb Company LAG-3 combination therapy for the treatment of cancer
EP3842550A4 (en) * 2018-08-24 2022-06-29 Repertoire Genesis Incorporation Method for analyzing functional subunit pair gene of t cell receptor and b cell receptor
US20210395392A1 (en) 2018-10-09 2021-12-23 Bristol-Myers Squibb Company Anti-mertk antibodies for treating cancer
WO2020081928A1 (en) 2018-10-19 2020-04-23 Bristol-Myers Squibb Company Combination therapy for melanoma
JP2022505647A (ja) 2018-10-23 2022-01-14 ブリストル-マイヤーズ スクイブ カンパニー 腫瘍の処置方法
MX2021005708A (es) 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
MX2021006578A (es) * 2018-12-05 2021-07-07 Genentech Inc Procedimientos de diagnostico y composiciones para la inmunoterapia contra el cancer.
CN109735558B (zh) * 2018-12-12 2022-04-15 中南大学 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用
WO2020198676A1 (en) 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Methods of treating tumor
KR20210146348A (ko) 2019-03-28 2021-12-03 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
JP2022534982A (ja) 2019-05-30 2022-08-04 ブリストル-マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよびその使用
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
JP7337373B2 (ja) * 2019-07-29 2023-09-04 サイアス株式会社 抗原特異的t細胞の製造方法
WO2021055994A1 (en) 2019-09-22 2021-03-25 Bristol-Myers Squibb Company Quantitative spatial profiling for lag-3 antagonist therapy
CN114728070A (zh) 2019-09-25 2022-07-08 百时美施贵宝公司 用于癌症疗法的复合生物标记物
WO2021092044A1 (en) 2019-11-05 2021-05-14 Bristol-Myers Squibb Company M-protein assays and uses thereof
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
EP4054723A1 (en) 2019-11-08 2022-09-14 Bristol-Myers Squibb Company Lag-3 antagonist therapy for melanoma
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides
WO2021127554A1 (en) 2019-12-19 2021-06-24 Bristol-Myers Squibb Company Combinations of dgk inhibitors and checkpoint antagonists
AU2021213969A1 (en) 2020-01-30 2022-09-01 ONA Therapeutics S.L. Combination therapy for treatment of cancer and cancer metastasis
WO2021158938A1 (en) 2020-02-06 2021-08-12 Bristol-Myers Squibb Company Il-10 and uses thereof
WO2021176424A1 (en) 2020-03-06 2021-09-10 Ona Therapeutics, S.L. Anti-cd36 antibodies and their use to treat cancer
AU2021244200A1 (en) 2020-03-23 2022-11-24 Bristol-Myers Squibb Company Anti-CCR8 antibodies for treating cancer
US20210393743A1 (en) * 2020-06-21 2021-12-23 Ketan Desai Use of IL13 for prevention and treatment of COVID19
MX2023002332A (es) 2020-08-28 2023-03-21 Bristol Myers Squibb Co Terapia con antagonistas del gen 3 de activacion de linfocitos (lag-3) para carcinoma hepatocelular.
IL300916A (en) 2020-08-31 2023-04-01 Bristol Myers Squibb Co Cell localization signature and immunotherapy
JP2023544410A (ja) 2020-10-05 2023-10-23 ブリストル-マイヤーズ スクイブ カンパニー タンパク質を濃縮するための方法
CA3196496A1 (en) 2020-10-23 2022-04-28 Laurence David TOMS Lag-3 antagonist therapy for lung cancer
CA3196535A1 (en) 2020-10-28 2022-05-05 Alfredo C. Castro Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
PT4267105T (pt) 2020-12-28 2025-04-30 Bristol Myers Squibb Co Composições de anticorpos e métodos de utilização das mesmas
AU2021416156A1 (en) 2020-12-28 2023-06-22 Bristol-Myers Squibb Company Methods of treating tumors
CN117858719A (zh) 2021-03-29 2024-04-09 朱诺治疗学股份有限公司 使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型cdcp1に対する抗体およびその使用
CA3226281A1 (en) 2021-07-30 2023-02-02 ONA Therapeutics S.L. Anti-cd36 antibodies and their use to treat cancer
WO2023077090A1 (en) 2021-10-29 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
AU2023213937A1 (en) 2022-01-26 2024-07-18 Bristol-Myers Squibb Company Combination therapy for hepatocellular carcinoma
KR20240153583A (ko) 2022-02-25 2024-10-23 브리스톨-마이어스 스큅 컴퍼니 결장직장암종에 대한 병용 요법
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
CN119156403A (zh) 2022-03-08 2024-12-17 阿伦蒂斯治疗股份公司 抗紧密连接蛋白-1抗体增加t细胞可用性的用途
US20250206775A1 (en) 2022-03-18 2025-06-26 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023196987A1 (en) 2022-04-07 2023-10-12 Bristol-Myers Squibb Company Methods of treating tumor
JP7851417B2 (ja) 2022-04-08 2026-04-24 ブリストル-マイヤーズ スクイブ カンパニー 三次リンパ組織様構造の機械学習識別、分類、及び定量化
AU2023281061A1 (en) 2022-06-02 2024-12-05 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
EP4310197A1 (en) 2022-07-21 2024-01-24 Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy
CN120379691A (zh) 2022-09-30 2025-07-25 爱兰蒂斯疗法股份公司 耐药性肝细胞癌的治疗
AU2023403103A1 (en) 2022-12-01 2025-07-10 Medimmune Limited Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
KR20250123912A (ko) 2022-12-21 2025-08-18 브리스톨-마이어스 스큅 컴퍼니 폐암에 대한 병용 요법
WO2024150177A1 (en) 2023-01-11 2024-07-18 Advesya Treatment methods for solid tumors
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2024261239A1 (en) 2023-06-23 2024-12-26 Imcheck Therapeutics Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis
CN121712571A (zh) 2023-08-15 2026-03-20 百时美施贵宝公司 陶瓷羟基磷灰石色谱流通法
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
US12521446B2 (en) 2024-02-27 2026-01-13 Bristol-Myers Squibb Company Anti-CEACAM5 antibody drug conjugates
US20250361320A1 (en) 2024-02-27 2025-11-27 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2025245489A1 (en) 2024-05-24 2025-11-27 Bristol-Myers Squibb Company Treatment of tumors in subjects having fgl-1 positive samples
WO2026096695A1 (en) 2024-10-31 2026-05-07 Bristol-Myers Squibb Company Anti-fucosyl-gm1 antibody drug conjugates
US20260144885A1 (en) 2024-11-22 2026-05-28 Bristol-Myers Squibb Company Anti-lrrc15 antibodies and uses thereof
US20260144884A1 (en) 2024-11-22 2026-05-28 Bristol-Myers Squibb Company Anti-lrrc15 antibody drug conjugates

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
NZ597098A (en) 2006-09-28 2013-05-31 Merck Sharp & Dohme Use of pegylated il-10 to treat cancer
ES2957546T3 (es) 2008-12-17 2024-01-22 Merck Sharp & Dohme Producción de mono- y di-PEG-IL10; y usos
WO2012129514A1 (en) * 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
WO2013074916A1 (en) * 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
WO2014133567A1 (en) * 2013-03-01 2014-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor-reactive t cells from tumor
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
GB201319160D0 (en) * 2013-10-30 2013-12-11 Imcyse Sa Methods for induction of antigen-specific regulatory t cells
KR20160079114A (ko) 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
WO2015108785A1 (en) * 2014-01-15 2015-07-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP3097117B1 (en) 2014-01-21 2023-10-04 Novartis Ag Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
WO2016191587A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
WO2017048614A1 (en) * 2015-09-15 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating tumor-reactive t cell receptors from tumor or peripheral blood

Also Published As

Publication number Publication date
CN108697776A (zh) 2018-10-23
EP3402512A4 (en) 2019-09-25
CA3008287A1 (en) 2017-07-20
EP3402512A1 (en) 2018-11-21
JP7082051B2 (ja) 2022-06-07
US20190032134A1 (en) 2019-01-31
AU2017207282A1 (en) 2018-07-05
KR20180101417A (ko) 2018-09-12
US11814679B2 (en) 2023-11-14
WO2017123557A1 (en) 2017-07-20
JP2019506843A (ja) 2019-03-14

Similar Documents

Publication Publication Date Title
MX2020004741A (es) Nuevos receptores de las celulas t modificados geneticamente y terapias immunologicas que emplean los mismos.
MX2019010972A (es) Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
AR127119A2 (es) Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores
MX2021001837A (es) Constructos del receptor de celulas t y usos de los mismos.
ECSP18073836A (es) Moléculas de unión a bcma y métodos de uso de las mismas
WO2016026854A3 (en) Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
MX2019006727A (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza.
CO2019006914A2 (es) Nuevos receptores de células t y terapia inmunológica que los utiliza
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
MX2019006724A (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza.
CL2018001369A1 (es) Composiciones y métodos usados para aumentar la respuesta inmune y en la terapia de cáncer (divisional solicitud 201700836)
MX2022005955A (es) Metodos y composiciones para terapia celular adoptiva.
MX2017001008A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33.
MX2019001769A (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
MX2021004294A (es) Suministro mejorado de particulas virales al cuerpo estriado y al cortex.
MX2017000646A (es) Celulas geneticamente modificadas para terapia celular adoptiva.
WO2014160030A3 (en) Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
MX2017006408A (es) Linfocitos t gamma delta modificados geneticamente.
MX2017002205A (es) Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
MX2020007338A (es) Composiciones y métodos para el direccionamiento a tipos de cáncer que expresan clec12a.
BR112016013187A2 (pt) receptores de antígenos quiméricos de mesotelina humanos e usos dos mesmos
CO2020006443A2 (es) Métodos y composiciones para la dosificación de células t con receptor de antígeno quimérico alogénicas
MX2019002998A (es) Celulas t con resistencia incrementada a la inmunosupresion.
MX2016010998A (es) Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados.
CO2017009922A2 (es) Péptidos y combinación de péptidos para inmunoterapia contra diversos tumores